Effect of lysosomal and ubiquitin-proteasome system dysfunction on the abnormal aggregation of α-synuclein in PC12 cells

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2088-2094

  Wang, Runqing ^a   Zhao, Jie ^a   Zhang, Jiewen ^b   Liu, Wei ^a   Zhao, Meiying ^a   Li, Jiangtao ^a   Lv, Juan ^a   Li, Yanan ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Lysosomes; PC12 cell; Ubiquitin proteasome; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DYE; LACTACYSTIN; LYSOSOME ENZYME; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NERVE GROWTH FACTOR; PROTEASOME; THIOFLAVIN S; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE; MTT ASSAY; NECROSIS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHEOCHROMOCYTOMA CELL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RAT;

EID: 84928256056     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2432     Document Type: Article

References (32)

1. Ghosh A, Roy A, Liu X, et al: Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 104: 18754-18759, 2007.
2. Bennett MC: The role of alpha-synuclein in neurodegenerative diseases. Pharmaco1 Ther 105: 311-331, 2005.
3. Bisaglia M, Mammi S and Bubacco L: Structural insights on physiological functions and pathological effects and alpha-synuclein. FASEB J 23: 329-340, 2009.
4. Nemani VM, Lu W, Berge V, et al: Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79, 2010.
5. Xu J, Kao SY, Lee FJ, Song W, Jin LW and Yankner BA: Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8: 600-606, 2002.
6. Yamanka K, Saito Y, Yamamori T, Urano Y and Noguchi N: 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem 286: 24666-34673, 2011.
7. Beyer K and Ariza A: Protein aggregation mechanism in synucleinopathies: Commonalities and differences. J Neuropathol Exp Neurol 66: 965-974, 2007.
8. Hu X, Zhang H, Zhang Y, et al: Differential protein profile of PC12 cells exposed to proteasomal inhibitor lactacystin. Neurosci Lett 575: 25-30, 2014.
9. Ryu EJ, Angelastro JM and Greene LA: Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis 18: 54-74, 2005.
10. McNaught KS, Shashidharan P, Perl DP, Jenner P and Olanow CW: Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 16: 2136-2148, 2002.
11. Pouplana S, Espargaro A, Galdeano C, et al: Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors. Curr Med Chem 21: 1152-1159, 2014.
12. Maroteaux L, Campanelli JT and Scheller RH: Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8: 2804-2815, 1988.
13. Jo E, McLaurin J, Yip CM, St George-Hyslop P and Fraser PE: alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275: 34328-34334, 2000.
14. McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P and Olanow CW: Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13: 1437-1441, 2002.
15. Banerjee K, Munshi S, Sen O, Pramanik V, Roy Mukherjee T and Chakrabarti S: Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: Potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson's disease. Parkinsons Dis 2014: 878935, 2014.
16. Bucciantini M, Giannoni E, Chiti F, et al: Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511, 2002.
17. Ciechanover A: The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 17: 7151-7160, 1998.
18. Česen MH, Pegan K, Spes A and Turk B: Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318: 1245-1251, 2012.
19. Boya P and Kroemer G: Lysosomal membrane permeabilization in cell death. Oncogene 27: 6434-6451, 2008.
20. Webb JL, Ravikumar B, Atkins J, Skepper JN and Rubinsztein DC: Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278: 25009-25013, 2003.
21. Shin Y, Klucken J, Patterson C, Hyman BT and McLean PJ: The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 280: 23727-23734, 2005.
22. Lazzeri G, Lenzi P, Busceti CL, et al: Mechanisms involved in the formation of dopamine-induced intracellular bodies within striatal neurons. J Neurochem 101: 1414-1427, 2007.
23. Jeon SM, Cheon SM, Bae HR, Kim JW and Kim SU: Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis. Exp Neurobiol 19: 155-164, 2010.
24. Lee HJ, Khoshaghideh F, Patel S and Lee SJ: Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24: 1888-1896, 2004.
25. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT and Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295, 2004.
26. Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, Von Figura K and Saftig P: Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell 13: 3355-3368, 2002.
27. Gu W and Silverman RB: Stereospecific total syntheses of proteasome inhibitor omuralide and lactacystin. J Org Chem 76: 8287-8293, 2011.
28. Wijayanti MA, Sholikhah EN, Hadanu R, Jumina J, Supargiyono S and Mustofa M: Additive in vitro antiplasmodial effect of N-alkyl and N-benzyl-1,10-phenanthroline derivatives and cysteine protease inhibitor e64. Malar Res Treat 2010: 540786, 2010.
29. Mo JS, Yoon JH, Hong JA, et al: Phosphorylation of nicastrin by SGK1 leads to its degradation through lysosomal and proteasomal pathways. PLoS One 7: e37111, 2012.
30. Rideout HJ and Stefanis L: Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21: 223-238, 2002.
31. Anglade P, Vyas S, Javoy-Agid F, et al: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12: 25-31, 1997.
32. Tain LS, Chowdhury RB, Tao RN, et al: Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK 1independently from Parkin. Cell Death Differ 16: 1118-1125, 2009.